Stevanato Group (NYSE:STVN) Director Purchases €326,750.00 in Stock

Stevanato Group S.p.A. (NYSE:STVN) Director Donald Morel, Jr. acquired 25,000 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average price of €13.07 per share, with a total value of €326,750.00. Following the completion of the purchase, the director owned 62,424 shares in the company, valued at €815,881.68. This trade represents a 66.80% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Stevanato Group Price Performance

NYSE STVN opened at €14.33 on Friday. Stevanato Group S.p.A. has a 12 month low of €12.05 and a 12 month high of €24.01. The stock has a market cap of $4.34 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 1.44 and a beta of 0.80. The company’s 50 day moving average is €19.23 and its two-hundred day moving average is €17.92. The company has a current ratio of 1.73, a quick ratio of 1.19 and a debt-to-equity ratio of 0.22.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). The firm had revenue of €326.06 million during the quarter. Stevanato Group had a return on equity of 10.51% and a net margin of 11.24%. As a group, research analysts anticipate that Stevanato Group S.p.A. will post 0.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on STVN. Weiss Ratings raised shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Citigroup dropped their price objective on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. UBS Group dropped their price objective on shares of Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, November 4th. Deutsche Bank started coverage on shares of Stevanato Group in a report on Wednesday, October 7th. They issued a “hold” rating on the stock. Finally, William Blair cut shares of Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy”.

Hedge Funds Weigh In On Stevanato Group

Several large investors have recently modified their holdings of STVN. Wellington Management Group LLP bought a new stake in Stevanato Group in the second quarter worth $22,621,000. Ranger Investment Management L.P. bought a new position in Stevanato Group during the second quarter valued at $21,438,000. Cooper Investors PTY Ltd. raised its stake in shares of Stevanato Group by 4.4% in the second quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company’s stock valued at $12,080,000 after acquiring an additional 28,265 shares during the period. Schwartz Investment Counsel Inc. raised its stake in shares of Stevanato Group by 15.0% in the third quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock valued at $13,871,000 after acquiring an additional 86,385 shares during the period. Finally, Riverbridge Partners LLC raised its stake in shares of Stevanato Group by 4.2% in the third quarter. Riverbridge Partners LLC now owns 625,914 shares of the company’s stock valued at $13,132,000 after acquiring an additional 25,400 shares during the period.

About Stevanato Group

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.